Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce global or clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review